Skip to main content
SpringerLink
Log in

Significato clinico del dosaggio della tireoglobulina ultrasensibile nel carcinoma tiroideo differenziato

  • Rassegna
  • Published:
L'Endocrinologo Aims and scope

Sommario

Nei pazienti affetti da carcinoma differenziato della tiroide, la rilevanza clinica ed economica di un follow-up ottimale, attraverso test diagnostici accurati, è una questione fondamentale, considerando il grande numero di pazienti nel mondo che vi si sottopongono per tutta la vita. In questo contesto, la recente introduzione nella pratica clinica di metodiche ultrasensibili per il dosaggio della tireoglobulina (Tg, sensibilità funzionale di 0,1 ng/ml) ha sensibilmente migliorato l’impiego clinico della Tg in terapia con ormoni tiroidei nel follow-up dei pazienti con carcinoma differenziato della tiroide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Bibliografia

  1. Cooper DS, Doherty GM, Haugen BR et al. (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109–142

    Article  PubMed  Google Scholar 

  2. Smallridge RC, Meek SE, Morgan MA et al. (2007) Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92:82–87

    Article  CAS  PubMed  Google Scholar 

  3. Iervasi A, Iervasi G, Ferdeghini M et al. (2007) Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol 67:434–441

    Article  CAS  Google Scholar 

  4. Rosario PW, Purisch S (2008) Does a highly sensitive thyroglobulin (Tg) assay change the clinical management of low-risk patients with thyroid cancer with Tg on T4<1 ng/ml determined by traditional assays? Clin Endocrinol 68:338–342

    CAS  Google Scholar 

  5. Spencer C, Fatemi S, Singer P et al. (2010) Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 20:587–595

    Article  CAS  PubMed  Google Scholar 

  6. Schlumberger M, Hitzel A, Toubert ME et al. (2007) Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 92:2487–2495

    Article  CAS  PubMed  Google Scholar 

  7. Castagna MG, Tala Jury HP, Cipri C et al. (2011) The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma. J Endocrinol Invest 34:219–223

    Google Scholar 

  8. Malandrino P, Latina A, Marescalco S et al. (2011) Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 96:1703–1709

    Article  CAS  PubMed  Google Scholar 

  9. Brassard M, Borget I, Edet-Sanson A et al. (2011) Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352–1359

    Article  CAS  PubMed  Google Scholar 

  10. Chindris AM, Diehl NN, Crook JE et al. (2012) Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 97:2714–2723

    Article  CAS  PubMed  Google Scholar 

  11. Rosario PW, dos Santos JB, Calsolari MR (2013) Follow-up of patients with low-risk papillary thyroid carcinoma and undetectable basal serum thyroglobulin after ablation measured with a sensitive assay: a prospective study. Horm Metab Res 45:911–914

    Article  CAS  PubMed  Google Scholar 

  12. Zöphel K, Wunderlich G, Smith BR (2003) Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 13:861–865

    Article  PubMed  Google Scholar 

Download references

Conflitto di interesse

L’autrice Maria Grazia Castagna dichiara di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

L’autrice di questo articolo non ha eseguito studi sugli animali.

Author information

Authors and Affiliations

  1. Sezione di Endocrinologia, Azienda Ospedaliera Universitaria Senese, Viale Bracci 1, 53100, Siena, Italia

    Maria Grazia Castagna

  2. Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Sezione di Endocrinologia e Malattie Metaboliche, Università di Siena, Siena, Italia

    Maria Grazia Castagna

Authors
  1. Maria Grazia Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria Grazia Castagna.

Additional information

Proposta da Michele Marinò.

Materiale elettronico supplementare

I link al materiale elettronico supplementare sono elencati qui sotto.

(DOC 27 kB)

(DOC 27 kB)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castagna, M.G. Significato clinico del dosaggio della tireoglobulina ultrasensibile nel carcinoma tiroideo differenziato. L'Endocrinologo 15, 60–64 (2014). https://doi.org/10.1007/s40619-014-0018-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-014-0018-9

Parole chiave

Search

Navigation